IndustryCompany release

CytoSorbents reaches operating cash flow breakeven in Q3 as operating loss narrows 59%

🇺🇸 Cytosorbents Corp (CTSO) · Thu 19 Nov 2026

The blood purification company reports 3% revenue growth to $9.7M, a 75% gross margin and lower costs, alongside an update on its DrugSorb-ATR US market pursuit.

CytoSorbents Corp has reported results for the third quarter of 2026, which ended on 30 September. Revenue rose 3% to $9.7M, and the company said its operating loss narrowed by 59%.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Cytosorbents Corp ↗

Article written by VigiEye from the official source (Cytosorbents Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →